Eli Lilly & Co. (LLY) — Analysis Summary
Eli Lilly & Co. (LLY) has a market cap of $1.05T with year-over-year revenue growth of +44.7%. Net margin stands at 31.7%. The stock trades at a P/E ratio of 39.2.
Key Takeaways
- Revenue changed +44.7% year-over-year
- Net margin of 31.7%
- P/E ratio of 39.2
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, LLY posted revenue growth of +44.7% and trades at a P/E of 39.2.
Eli Lilly & Co. (LLY)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
50,000
Headquarters
INDIANAPOLIS, IN
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$6.92
Dividend Yield
0.59%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.